https://sciex.com/content/SCIEX/na/us/en


The Promise of Precision Medicine

Aug 26, 2016 | Blogs, Life Science Research, Proteomics | 0 comments

NIH awards $55 million to build million-person precision medicine study

Here is the latest update on the Worldwide Efforts to Accelerate Precision Medicine

The NIH recently issued a press release in early July announcing $55 million in awards. According to the release, the $55 million award in the fiscal year 2016 will go towards building the foundational partnerships and infrastructure needed to launch the Cohort Program of President Obama’s Precision Medicine Initiative (PMI). The PMI Cohort Program is a landmark longitudinal research effort that aims to engage 1 million or more U.S. participants to improve the ability to prevent and treat disease based on individual differences in lifestyle, environment, and genetics.

The press release goes on the state that the PMI Cohort Program is one of the most ambitious research projects in history and will set the foundation for new ways of engaging people in research. PMI volunteers will be asked to contribute a wide range of health, environment and lifestyle information. They will also be invited to answer questions about their health history and status, share their genomic and other biological information through simple blood and urine tests and grant access to their clinical data from electronic health records. Also, mobile health devices and apps will provide lifestyle data and environmental exposures in real time.  All of this will be accomplished with essential privacy and security safeguards.  As partners in the research, participants will have ongoing input into study design and implementation, as well as access to a wide range of their individual and aggregated study results.

The SCIEX Solution
As the promise of precision medicine continues to evolve; researchers will need powerful tools and application support to perform the Omics research at an industrialized scale that is sufficient to build the scientific foundation of precision medicine.

SCIEX has been focused on industrializing the proteomics solutions to enable large-scale proteome studies to advance research.   Centered around the microflow SWATH® acquisition strategy for collecting digital proteome maps, data processing has been moved to the cloud with the OneOmics™ project to provide the compute power for processing these maps.  Protocols also have been automated to provide the reproducibility required, again at an appropriate scale to feed the pipeline.

The same principles have been applied to industrializing quantitative lipidomics, with the launch of the Lipidyzer™ Platform.

With SCIEX technologies, you can accelerate the pace of your research to identify key genes, proteins, lipids and metabolites in complex systems biology and then integrate your findings to gain a comprehensive insight to further understand health and disease.

Want to know more about available methods? Comment below!

References

  1. NIH Press Release- NIH awards $55 million to build million-person precision medicine study

Questions and answers to help improve your mycotoxin analysis

During a recent webinar I shared method details for mycotoxin analysis on the SCIEX 7500 system. In this blog i will share the Q&A for the submitted questions that we did not have chance to answer during the live webinar.

A 2-fold revolution: MS approaches for the bioanalysis of oligonucleotide therapeutics

In 1998, the US Food and Drug Administration (FDA) approved fomivirsen as the first therapeutic oligonucleotide therapeutic. This approval marked a revolution of mechanism of action discovered decades before finally coming to fruition. Since then, the landscape of chemical modifications of oligonucleotides, conjugations and formulations has evolved tremendously, contributing to improvements in stability, efficacy and safety. Today, more than a dozen antisense oligonucleotides (ASOs) and small interfering RNA (siRNA) drugs are on the market, most of which are designated as orphan drugs for treating rare genetic diseases.

Is “right first time, every time” a pipedream for metabolite identification by LC-MS?

If we lived in an ideal world, it would be possible to unambiguously identify metabolites using a single analytical experiment. This analytical technique would need to be efficient and easily generate the information needed from a routine assay that is also robust, enabling confident decision-making during drug discovery.

Posted by

0 Comments

Submit a Comment

Wordpress Social Share Plugin powered by Ultimatelysocial